{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:58Z","timestamp":1761831418192,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jacl.2011.06.010","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T11:59:58Z","timestamp":1309435198000},"page":"401-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (\u22652 mg\/L)"],"prefix":"10.1016","volume":"5","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn M.","family":"Setze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen T.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.06.010_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.06.010_bib2","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and C-reactive protein <2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.06.010_bib3","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.jacc.2009.10.006","article-title":"Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study","volume":"54","author":"Yang","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.06.010_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.06.010_bib5","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.06.010_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jacc.2005.08.024","article-title":"Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.06.010_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2011.06.010_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2008.09.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study","volume":"204","author":"Jones","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2011.06.010_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10557-010-6266-4","article-title":"Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia\u2013a phase 3 study","volume":"24","author":"Roth","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2011.06.010_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacl.2008.10.001","article-title":"Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia","volume":"2","author":"Bays","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2011.06.010_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/00044011-200828100-00003","article-title":"Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins","volume":"28","author":"Jones","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jacl.2011.06.010_bib12","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.06.010_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11319800-000000000-00000","article-title":"Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study","volume":"30","author":"Kipnes","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jacl.2011.06.010_bib14","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:32:57Z","timestamp":1761831177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411006179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1933287411006179"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.06.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (\u22652 mg\/L)","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2011.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}